RAC1 and breast carcinoma: EHop-016 is known to be >100-fold more potent than previous Rac1 inhibitors such as NSC23766 in metastatic breast cancer cells, and our data provide an opportunity for the further development of EHop-016 [37], or its analogs, for the precision drugging of aggressive RAC1-altered HNSCC.